Dimensional Fund Advisors LP Acquires New Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Dimensional Fund Advisors LP acquired a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 16,580 shares of the company’s stock, valued at approximately $105,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in shares of ImmunityBio during the fourth quarter worth $304,000. Brookstone Capital Management acquired a new stake in shares of ImmunityBio during the 1st quarter valued at about $100,000. Courier Capital LLC grew its stake in shares of ImmunityBio by 33.3% in the 1st quarter. Courier Capital LLC now owns 20,000 shares of the company’s stock valued at $107,000 after buying an additional 5,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in ImmunityBio by 41.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,411 shares of the company’s stock worth $319,000 after buying an additional 17,549 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in ImmunityBio by 9.3% during the first quarter. ProShare Advisors LLC now owns 70,613 shares of the company’s stock valued at $379,000 after acquiring an additional 6,004 shares in the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Price Performance

ImmunityBio stock opened at $3.70 on Wednesday. ImmunityBio, Inc. has a one year low of $1.25 and a one year high of $10.53. The company’s fifty day moving average price is $3.76 and its two-hundred day moving average price is $5.44. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of -3.39 and a beta of 1.02.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $1.05 million during the quarter, compared to analyst estimates of $2.53 million. As a group, sell-side analysts anticipate that ImmunityBio, Inc. will post -0.86 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Piper Sandler decreased their target price on shares of ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a research report on Monday, August 19th.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.